Galderma and NovaBay begin Phase 2b trial for impetigo

Tweet Galderma S.A. and NovaBay Pharmaceuticals (AMEX:NBY) said on Monday the first patients have been enrolled in their Phase 2b clinical study of a proprietary topical formulation of NovaBay’s NVC-422 for the treatment of impetigo. The study is expected to enroll over 300 patients at 24 clinical sites in four countries and aims to confirm [...]

Innovotech targets personalized medicine for bacteria

Tweet Ken Boutilier doesn’t mince words. “We believe we are pursuing the greatest opportunity in microbiology since penicillin,” the CEO of Innovotech (TSX-V:IOT) says in an exclusive interview with biotuesdays.com. “That’s our fundamental belief. For as good as penicillin and subsequent antibiotics after it were, they missed a very important fact about bacteria: bacteria exist [...]